Literature DB >> 14498756

Tadalafil.

Monique Curran1, Gillian Keating.   

Abstract

black triangle Tadalafil is a selective phosphodiesterase type 5 inhibitor that is effective in men with mild-to-severe erectile dysfunction (ED), including those with diabetes mellitus. black triangle The improvement in the erectile function domain score on the International Index of Erectile Function (IIEF) and the percentage of sexual intercourse attempts marked by successful vaginal penetration and completion was significantly greater with on-demand (not more than once daily) tadalafil 10 or 20 mg than placebo in trials of 12 weeks' duration. Improvement in scores on other domains of the IIEF and the percentage of positive responses to a Global Assessment Question measuring erection improvement were also significantly greater with on-demand tadalafil than placebo. black triangle The adverse events associated with tadalafil were generally mild to moderate and decreased in frequency with continued administration. The most commonly reported adverse events were headache and dyspepsia. The incidence of cardiovascular adverse events was not significantly different in tadalafil or placebo recipients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14498756     DOI: 10.2165/00003495-200363200-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function.

Authors:  K Marumo; J Nakashima; M Murai
Journal:  Int J Urol       Date:  2001-02       Impact factor: 3.369

2.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

3.  Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity.

Authors:  M H Blanker; J L Bosch; F P Groeneveld; A M Bohnen; A Prins; S Thomas; W C Hop
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

4.  On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction.

Authors:  H Padma-Nathan; J G McMurray; W E Pullman; J S Whitaker; J B Saoud; K M Ferguson; R C Rosen
Journal:  Int J Impot Res       Date:  2001-02       Impact factor: 2.896

Review 5.  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.

Authors: 
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

6.  Effects of tadalafil on erectile dysfunction in men with diabetes.

Authors:  Iñigo Sáenz de Tejada; Greg Anglin; James R Knight; Jeffrey T Emmick
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

Review 7.  IC351 (tadalafil, Cialis): update on clinical experience.

Authors:  H Porst
Journal:  Int J Impot Res       Date:  2002-02       Impact factor: 2.896

8.  Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

Authors:  Hartmut Porst; Harin Padma-Nathan; François Giuliano; Greg Anglin; Lucio Varanese; Raymond Rosen
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

9.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.

Authors:  Gerald B Brock; Chris G McMahon; K K Chen; Timothy Costigan; Wei Shen; Vish Watkins; Greg Anglin; Steve Whitaker
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

10.  Phosphodiesterase inhibitors in the treatment of erectile dysfunction.

Authors:  M C Truss; C G Stief
Journal:  Drugs Today (Barc)       Date:  1998-09       Impact factor: 2.245

View more
  15 in total

1.  Efficacy of tadalafil treatment on erectile dysfunction in patients under dutasteride treatment: A prospective non-randomized comparative study.

Authors:  Mete Özkıdık; Mehmet İlker Gökce; Önder Yaman
Journal:  Turk J Urol       Date:  2018-07

Review 2.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

Review 3.  Tadalafil: in pulmonary arterial hypertension.

Authors:  Jamie D Croxtall; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

Review 4.  Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

5.  A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma.

Authors:  Christine A Farthing; Don E Farthing; Saisudha Koka; Terri Larus; Itaf Fakhry; Lei Xi; Rakesh C Kukreja; Domenic Sica; Todd W B Gehr
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-08-03       Impact factor: 3.205

6.  Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

Authors:  S Thomas Forgue; Diane L Phillips; Alun W Bedding; Christopher D Payne; Hayley Jewell; Beverley E Patterson; Rebecca E Wrishko; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

Review 7.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

9.  Tadalafil pharmacokinetics in healthy subjects.

Authors:  S Thomas Forgue; Beverley E Patterson; Alun W Bedding; Christopher D Payne; Diane L Phillips; Rebecca E Wrishko; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

10.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.